London: AstraZeneca‘s blockbuster diabetes drug Farxiga led to significant reductions in the risk of hospitalisation and death in people with all types of heart failure, according to study data released on Saturday, opening the door to a substantial increase in patients who could benefit.
The drug belongs to a class of medicines called SGLT2 inhibitors that were initially approved to treat type 2 diabetes. Since then, the drugs have been shown…